44 results about "Osteopontin" patented technology

The invention provides a nutrition enhancer beneficial to bone health of middle-aged and elderly people, a preparation method of the nutrition enhancer and application of the nutrition enhancer in preparation of medial care food, and belongs to the field of nutritious food. The nutrient supplement comprises a plant fermentation product, osteopontin peptide, collagen peptide, N-acetylglucosamine and calcium, vitamins and mineral substances can be added, and the plant fermentation product is obtained by performing anaerobic fermentation on rhizoma drynariae and chestnuts through a complex microbial inoculant composed of lactobacillus reuteri and bifidobacterium longum subsp. Longum; the collagen peptide is prepared by performing enzymolysis on bovine bones through alkaline protease and flavourzyme; the hydrogel is prepared by adopting a sodium alginate-calcium chloride-carboxymethyl chitosan micro-capsule embedding process. An in-vitro experiment shows that the nutrition enhancer can remarkably promote osteoblast proliferation, differentiation and mineralization; animal experiments show that the bone mineral density of osteoporosis model mice can be effectively improved. The nutrition enhancer disclosed by the invention is suitable for preparing care food and bone health products, and has a remarkable effect of improving bone health of middle-aged and elderly people.

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.

The application discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. The composition is prepared by using 1,3-dioleic acid-2-palmitic acid triglyceride, osteonectin and oligosaccharide in combination, and through the interaction between the components, the absorption and utilization of each other are promoted, the growth and development of the bone of an infant in the growth period are improved, the bone mineral content and bone density are improved, the bone health is promoted, and the composition is safe and has no side effect. Through optimization of the types of the oligosaccharide, it is found that the combination of oligogalactose and 2'-fucosyllactose can better improve the growth and development of the bone of the infant in the growth period.

The invention belongs to the technical field of pharmaceutical compositions, and particularly relates to a composition helpful for improving bone mineral density and application thereof. The composition comprises sheep milk casein peptide, collagen tripeptide, sea cucumber peptide and osteopontin, can achieve the effects of improving bone mineral density and preventing and treating osteoporosis, integrates functionality and nutrition, and has wide application prospects in the aspect of promoting calcium absorption.

The invention discloses a preparation technology of a lactoferrin and osteopontin compound capable of improving bone health, and belongs to the technical field of food processing. In the compound, the mass ratio of lactoferrin to osteopontin is (3-5): 1, and the pH is 4-5.5. In a zebra fish model, after intervention of the lactoferrin, the osteopontin, the compound or the mixture, compared with a mixture group, the compound group of the lactoferrin and the osteopontin can obviously improve the fluorescence intensity of zebra fish spines, the relative bone mineral density is improved by 31.12%, and compared with a blank group, the relative bone mineral density is improved by 2.39 times. Therefore, the lactoferrin and osteopontin compound with the function of improving bone health can be prepared, and the lactoferrin and osteopontin compound has good application potential.

The invention relates to the technical field of biology, in particular to application of osteopontin in regulation of intestinal anaerobic symbiotic bacteria colonization. The osteopontin is used for preparing food or medicine for improving the immunity of the intestinal tract, and the food or medicine is used for improving the abundance of anaerobic symbiotic bacteria in the intestinal tract; according to the application disclosed by the invention, firstly, by virtue of transcriptome analysis, it is proved that the abundance of Parabacteroids distans and Blautiapseudococcoids can be remarkably improved by virtue of the exogenous osteopontin, so that the abundance of the Parabacteroids distans and the abundance of the Blautiapseudococcoids can be remarkably improved; secondly, the invention also proves that the exogenous osteopontin can be used for inhibiting the proliferation of harmful bacteria Escherichia coli; therefore, the intestinal immunity is improved, the intestinal barrier is improved or repaired, and the intestinal flora balance is maintained. The composition is suitable for infants, old people, patients and other people with low immunity.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

The present invention relates to the use of urine protein as a diagnostic marker for primary biliary cholangitis (PBC). The urine protein includes one or a combination of osteopontin (OPN), receptor activity-modifying protein 3 (RAMP3), and calcium-binding protein (S100A8). This application uses urine as a non-invasive test sample, making it more readily accepted by patients than blood. It is of great significance for the early, non-invasive diagnosis of PBC patients.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

The application provides a composition for promoting bone health and bone formation, and application and products thereof, and belongs to the field of food. The composition of the application is composed of 2'-fucosyllactose, osteopontin and a calcium source, wherein the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight. The composition of the application shows a good synergistic effect in promoting calcium absorption, and can be used for increasing bone density, preventing and treating osteoporosis and the like.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

This invention relates to a combination comprising effective amounts of osteopontin and lactoferrin, for use in promoting the socio-emotional development of young individuals. The invention also relates to compositions and methods for promoting the socio-emotional development of young individuals, preferably infants.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

This invention relates to the field of food processing technology, and more particularly to a method and application for separating bovine colostrum whey. The method for separating bovine colostrum whey provided by this invention includes: mixing and adjusting bovine colostrum collected at different time points within 72 hours of calving to a raw milk with a total solids content of 14-20%; the raw milk is then defatted and enzymatically hydrolyzed to separate the whey; wherein the defatting temperature is 35-50℃. The method provided by this invention can efficiently separate and prepare bovine colostrum whey, with a whey extraction rate ≥70%. The obtained bovine colostrum whey has a high content of various active proteins. The obtained bovine colostrum whey can be used to prepare functional raw materials such as immunoglobulins, lactoferrin, and osteopontin.

Disclosed herein are methods of treatment for diseases and disorders with modulators of full-length or thrombin-cleaved osteopontin. Particularly disclosed herein are methods comprising treatment of tissue fibrosis (e.g., pulmonary, cardiac, liver, kidney, skin) with antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin.

The application discloses application of a composition in preparation of a product for improving constipation, and belongs to the technical field of food. The application adopts OPO, osteopontin and specific oligosaccharides in combination, promotes absorption and utilization of functional components such as minerals and fatty acids through interaction between the components, improves constipation of infants, regulates basal energy intake and intestinal health, and promotes growth and development of the infants.

The invention relates to a method for separating and purifying osteopontin from human milk, which comprises the following steps: (1) pretreatment: collecting human milk and pretreating the human milk to remove fat and cell debris impurities to obtain pretreated emulsion; (2) osteopontin precipitation: adding a precipitator into the pretreated emulsion to precipitate osteopontin, and collecting the precipitate; (3) osteopontin dissolution: adding a solvent capable of dissolving osteopontin into the obtained precipitate, fully mixing, and then removing insoluble substances to obtain an osteopontin crude solution; (4) dialyzing and concentrating: dialyzing and concentrating the osteopontin crude solution to obtain an osteopontin concentrated solution; (5) chromatography: purifying the osteopontin concentrated solution in a chromatography manner to obtain an osteopontin purified solution; and (6) drying: drying the osteopontin purified liquid to obtain osteopontin powder. By adopting the method disclosed by the invention, the osteopontin purity of 95% or more by mass can be efficiently realized.

The invention relates to the technical field of molecular biology and biological medicine, in particular to siRNA with skin cell aging resisting and repairing effects and application of the siRNA. The siRNA comprises a guide chain and a passenger chain. And the siRNA is used for targeting an osteopontin coding gene SPP1. The siRNA has an excellent anti-aging effect and can be used for preparing anti-aging products.

This invention relates to a nutritional composition comprising osteopontin as an active ingredient, which is used to promote emotional development in young individuals, preferably infants. The invention also relates to uses and methods for promoting emotional development in young individuals, preferably infants.

The invention relates to the technical field of biological medicines, in particular to an osteopontin probiotic composition and application thereof to improvement of male reproductive health. The invention provides an osteopontin probiotic composition which comprises probiotics and osteopontin, and the probiotics are bifidobacterium longum subsp. Infantis B8762; the osteopontin comprises a cow milk source. The probiotics and the osteopontin are combined for application, key reproductive genes in testis can be effectively adjusted, reproductive dysfunction is relieved, and male reproductive health is improved.

The invention discloses an application of an expression inhibitor of a muscular blind splicing regulator 1 (MBNL1) in promoting osteogenic differentiation and bone formation of bone marrow mesenchymal stem cells (BMSCs), and particularly discloses an application of the expression inhibitor of the MBNL1 in promoting osteogenic differentiation and bone formation of the BMSCs (bone marrow mesenchymal stem cells). According to the present invention, the in-vitro experiment results prove that the si-MBNL1 transfection on the BMSCs can promote the formation of osteoblast calcium nodules, the activity of the marker enzyme ALP, and the expression of the osteogenic related factor Runt related transcription factor 2 (RUNX2), the ALP, the osteopontin (OPN) and the osteocalcin (OCN), and can improve the osteogenic differentiation ability of the BMSCs, such that the si-MBNL1 transfection on the BMSCs can provide the osteogenic differentiation ability of the BMSCs, and further provide the application of the si-MBNL1 transfection on the BMSCs, and the application of the si-MBNL1 transfection on the BMSCs to the osteogenic differentiation of the BMSCs, according to the invention, an adeno-associated virus 9 (AAV9) carrier is used for constructing an sh-MBNL1 regulation technology as an MBNL1 expression inhibitor, and in-vivo experiments prove that the sh-MBNL1 expression inhibitor can be used for repairing estrogen deficiency type osteoporosis bone loss and promoting fracture healing. According to the invention, a breakthrough direction is provided for clinical early warning of osteoporosis, and a new technical means is provided for clinical osteoporosis or gene therapy for promoting fracture healing.

The invention provides a method for screening functional monomers based on molecular simulation and preparing an osteopontin molecularly imprinted membrane, and belongs to the technical field of protein separation. The method comprises the following steps: acquiring an amino acid sequence of cow milk osteopontin from a Uniprot KB database, predicting and optimizing a three-dimensional structure of the cow milk osteopontin by utilizing a trRossetta server, screening a high-affinity ligand through molecular docking, verifying binding stability through molecular dynamics simulation, and finally determining a functional monomer. Then, the screened functional monomers, osteopontin, a cross-linking agent and the like are dissolved in a Tris-HCl buffer solution to form a pre-assembled solution, an initiator and a catalyst are added for polymerization, unreacted monomers are removed after the reaction is completed, template osteopontin is eluted, and the molecularly imprinted membrane is obtained. By adopting the method, the optimal imprinting system is predicted and screened out by utilizing a molecular simulation technology, the limitation of a traditional method is avoided, the cost is reduced, the prepared molecularly imprinted membrane has high-selectivity recognition characteristic on target protein, the stability is good, and the preparation method is simple and feasible.

Methods for characterizing disease activity in patients with systemic lupus erythematosus (SLE). These methods include obtaining blood, serum, plasma, or urine samples from the patient; assessing the expression of biomarkers selected from IFN-α, IL-10, BlyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4 in the samples; assessing the expression of inflammatory mediators selected from TNFRII, resistin, and osteopontin (OPN) in the samples; assessing SLE-related autoantibody-specific biomarkers selected from dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP in the samples; and calculating the Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score can distinguish between active and low lupus disease activity. Treatment methods are also provided, including administration after determining that the patient has a prognostic risk of transitioning to classified SLE but before reaching the clinical disease classification.

The present application relates to the field of molecular biology and biomedicine technology, and particularly relates to an siRNA with anti-skin cell aging and repair effect and application thereof.The siRNA comprises a guide chain and a passenger chain.The siRNA targets a bone bridge protein coding gene SPP1.The siRNA has excellent anti-aging effect and can be used for preparing anti-aging products.

The invention relates to the technical field of biological medicines, in particular to an osteopontin probiotic composition and application thereof in promoting intestinal development of infants. The invention provides an osteopontin probiotic composition, which comprises probiotics and osteopontin, and is characterized in that the probiotics are bifidobacterium longum subsp. Infantis B8762, the osteopontin probiotic composition is prepared from the probiotics and the osteopontin, and the osteopontin probiotic composition is prepared from the probiotics and the osteopontin. The osteopontin comprises a cow milk source. The probiotics and the osteopontin are combined for application, so that the intestinal barrier and the immune function of infants can be effectively improved, and the effect of promoting healthy development of intestinal tracts is achieved.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

The invention relates to a special medicine for aquaculture, in particular to an immunity improving composition for aquaculture and a preparation method. The invention discloses an immunity improving composition for aquaculture. The immunity improving composition is prepared from 15 to 25 parts of osteopontin, 15 to 25 parts of sericin, 10 to 15 parts of 6 '-sialic acid lactose, 100 to 120 parts of modified calcium hydrogen phosphate solution, 80 to 130 parts of compound, 10 to 30 parts of xanthan gum and 755 to 780 parts of water, water-soluble modified calcium hydrophosphate is adopted, so that intestinal absorption of aquatic animals is facilitated; the xanthan gum and the sericin form gel, so that the loss probability of soluble substances after the feed is mixed and put into water is reduced, and the probability that the soluble substances are swallowed by aquatic animals is further improved; the aquatic animals are prevented from being infected by harmful bacteria through the synergistic effect of various organic matters.

This invention provides a nutritional composition and its application. The nutritional composition comprises medium- and long-chain fatty acid triglycerides and osteopontin in a mass ratio of 6:1 to 1500:1, which have a synergistic effect in enhancing immunity, particularly in restoring one or more of the number of macrophages, T cells, and neutrophils in an individual.